First author, year | nation | Cancer type | Case number (High/Low) | Cut-off value | Detection method | Outcome | Follow-up time |
---|---|---|---|---|---|---|---|
Liu C,2020 [14] | China | CRC | 189 (92/97) | Positive cells: + | IHC | OS | > 140 months |
Wang L,2020 [16] | China | GC | 90 (55/35) | Score = 8 | IHC | OS | > 70 months |
Zhou R,2018 [18] | China | CRC | 116 (69/47) | Positive cells: + | IHC | OS | > 125 months |
Shen Q,2020 [19] | China | ESCC | 124 (65/59) | NA | IHC | OS | > 60 months |
Pan YB,2017 [20] | China | CRC | 286 (143/143) | NA | cDNA | RFS | 192 months |
Mao LX,2019 [21] | China | PC | 106 (70/36) | NA | IHC | NA | NA |
Kugimiya N,2017 [22] | Japan | CRC | 50 (17/33) | ROC | RT-PCR | RFS | > 38 months |
Liu HL,2018 [17] | China | HCC | 102 (73/29) | NA | IHC | OS | > 80 months |
Wang Y,2014 [23] | China | HCC | 67 (41/26) | Score = 3 | IHC | OS | 60 months |
Hsu MC,2008 [24] | China | HCC | 99 (37/62) | Staining color: T = N | IHC | NA | NA |
Chen L,2010 [15] | China | HCC | 76 (43/33) | Positive cells = 69% | IHC | OS | 60 months |
Wang F,2009 [25] | China | ESCC | 90 (75/15) | Positive cells = 10% | IHC | OS | 60 months |
Zheng L,2016 [26] | China | ESCC | 187 (122/65) | Positive cells = 50% | IHC | OS | > 45 months |
Guo ZQ,2014 [27] | China | CRC | 80 (66/14) | Positive cells = 30% | IHC | NA | NA |
Yang F,2013 [28] | China | GC | 80 (57/23) | Score = 1 | IHC | NA | NA |
Zhang SW,2014 [29] | China | CRC | 94 (81/13) | Score = 1 | IHC | NA | NA |
Cao Y,2013 [30] | China | HCC | 40 (28/12) | Positive cells = 25% | IHC | NA | NA |
Yang SH,2013 [31] | China | CRC | 74 (60/74) | Score = 1 | IHC | OS | 60 months |
Shi H,2010 [32] | China | ESCC | 60 (47/13) | Positive cells = 25% | IHC | NA | NA |
Gu GJ,2017 [33] | China | GBC | 65 (39/26) | Score = 3 | IHC | NA | NA |
Zhang LY,2011 [34] | China | ESCC | 58 (37/21) | Positive cells = 25% | IHC | NA | NA |
Li S,2012 [35] | China | GC | 60 (43/17) | Score = 1 | IHC | OS | > 60 months |